Javascript Disabled

This site requires Javascript in order to function properly. Please enable it in your browser's settings.

To reduce serum phosphate in patients with ESRD FOSRENOL Oral Powder:
Added to applesauce. Adding to administrative options.

  • FOSRENOL Oral Powder has been available since May 2015—the first FDA-approved phosphate binder that is specifically formulated to be mixed with applesauce or other similar food, and not liquid1
  • With the same active ingredient as FOSRENOL Chewable Tablets, FOSRENOL Oral Powder has shown to be comparable to the chewable tablets in a pharmacodynamic study.1,† A proven phosphate binder, FOSRENOL Chewable Tablets have been approved since 20041,2

Based on urinary phosphate excretion in healthy subjects.

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information .

Important Safety Information

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information.

References: 1. FOSRENOL [package insert]. Lexington, MA: Shire US Inc. 2. Center for Drug Evaluation and Research. FOSRENOL approval letter. US Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21468ltr.pdf. Published October 26, 2004. Accessed March 29, 2015.